Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

A synthetic microbiome therapy, tested in mice, protects against severe symptoms of a gut infection that is notoriously difficult-to-treat and potentially life threatening in humans, according to a ...

Clostridioides difficile, a bacteria that creates inflammation of the colon and causes symptoms like infectious diarrhea, is of particular risk among hospitalized patients. Findings of a new Polish ...

In a major step toward a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

Please provide your email address to receive an email when new articles are posted on . Rebyota was effective in real-world analyses, with results consistent with the PUNCH CD3 trial. Rebyota was also ...

Plus, get the best of BroadwayWorld delivered to your inbox, and unlimited access to our editorial content across the globe. In the new book, "Managing a C. difficile Infection: For Patients, Families ...

LA Times Studios produces content by working closely with scientists and healthcare experts as well as sourcing scholarly-reviewed medical and science journals and is independent of the L.A. Times ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Clostridium bacteria, computer illustration. Clostridia are spore-forming bacteria that include several human pathogenic species, C. difficile, C. tetani, C. botulinum, C. perfringens, and others. C.